Annals On Call Podcast podcast

Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes

0:00
29:55
Rewind 15 seconds
Fast Forward 15 seconds
Dr. Centor discusses outcomes in patients with type 2 diabetes when treated with semaglutide or dulaglutide versus empagliflozin with Drs. Kevin Kip and Anum Saeed.

More episodes from "Annals On Call Podcast"